Clinical trial
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase…
NCT00151502 · Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry · Completed
Key facts
| NCT number | NCT00151502 |
|---|---|
| Title | To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients. |
| Official title | An 80-Week, Randomized, Multi-Center, Parallel-Group, Double-Blind Study of the Efficacy and Safety of Atorvastatin 80 MG Plus an Acetylcholinesterase Inhibitor Versus an Acetylcholinesterase Inhibitor Alone in the Treatment of Mild to Moderate Alzheimer's Disease. |
| Lead sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer's Disease |
| Intervention type | Drug |
| Interventions | Atorvastatin |
| Enrollment | 600 |
| Start date | Nov 1, 2002 |
| Completion | Jul 1, 2007 |
| First posted | Sep 9, 2005 |
| Last update posted | Feb 18, 2021 |
| Countries | Australia, Austria, Canada, Denmark, Germany, South Africa, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: